Eli Lilly & Co. vs. SCYNEXIS, Inc.
Eli Lilly & Co. (LLY) comes out ahead, leading on 6 of 9 compared factors.
Size & Scale
| LLY | SCYX | |
|---|---|---|
| Market Cap | $1.03 trillion | $44.38 million |
| Revenue (TTM) | $79.67 billion | $19.21 million |
| Net Income (TTM) | $26.71 billion | $-10,235,000 |
LLY leads on 3 of 3 size & scale factors.
Valuation
| LLY | SCYX | |
|---|---|---|
| P/E Ratio | 38.91 | 14.86 |
| Price / Book | 30.33 | 0.66 |
| Price / Sales | 12.90 | 2.31 |
SCYX leads on 3 of 3 valuation factors.
Profitability
| LLY | SCYX | |
|---|---|---|
| Net Margin | 33.53% | -53.27% |
| Return on Equity | 78.84% | -15.29% |
LLY leads on 2 of 2 profitability factors.
Dividend
| LLY | SCYX | |
|---|---|---|
| Dividend Yield | 0.60% | — |
| Payout Ratio | 23.23 | — |
LLY and SCYX split the dividend factors evenly.
Risk & Sentiment
| LLY | SCYX | |
|---|---|---|
| Short Interest | 1.29% | 13.22% |
LLY leads on 1 of 1 risk & sentiment factors.
Dig deeper: LLY overview, LLY financials, SCYX overview, SCYX financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.